The 40th JPM 2022 Healthcare Conference was held from January 10th to 13th, with digital meetings continuing until the end of January, enabling exchanges among entreprises pharmaceutiques from around the world.
This meeting brought together a large number of national pharmaceutique and bio companies, notamment Samsung Biologics, making it an occasion to discuss global transferts de technologie.
With many national companies participating in the main track, emerging track, and Asia-Pacific sessions, RudaCure was also able to continue discussions on RCI001 and RCI002 with interested parties notamment Kintor, Qilu, Alimera Sciences, and AbbVie grâce à cela JPM conference.
Among these, AbbVie expressed significatif interest in RCI001, showing great enthusiasm for the essai clinique progress and expressing amazement at the drug's efficacy through its novel mécanisme d'action, hoping to establish an ongoing relationship. Chinese companies were also able to exchange information about market conditions in China.